Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...
Monthly Prescribing Reference

Qivigy Approved for Primary Humoral Immunodeficiency in Adults

The product is expected to be available in early 2026. The Food and Drug Administration (FDA) has approved Qivigy (immune globulin intravenous [IV], human-kthm) 10% solution for the treatment of ...
Healio

FDA approves Qivigy for adults with primary humoral immunodeficiency

Please provide your email address to receive an email when new articles are posted on . There were no serious bacterial infections or hospitalizations due to infection over 12 months among adults ...
Morningstar

Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase ...

QIVIGY is the realization of over 10 years of investments and internal efforts to bring a proprietary IVIG product from concept to commercialization FORT LEE, N.J., Sept. 29, 2025 /PRNewswire/ -- ...